Fig. 3From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancerCumulative survival analysis of overall survival of CRC patients with EGFR/HER2/c-MYC/MET GCN alteration, which were defined according to the following criteria: a amplification; b GCN gain; c ASCO/CAP criterionBack to article page